DVAX
- Dynavax Technologies Corporation
()
Overview
Company Summary
Dynavax Technologies Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative vaccines. The company's main goal is to provide protection against infectious diseases by developing vaccines that stimulate the immune system to produce a specific response.
Dynavax primarily specializes in the development of vaccines that target diseases such as hepatitis B, influenza, and COVID-19. Their proprietary technology platform, known as the Toll-like Receptor (TLR) biology, forms the basis for their vaccine candidates.
The company's most notable vaccine is HEPLISAV-B, which is designed to protect against hepatitis B infection. HEPLISAV-B has been approved by the U.S. Food and Drug Administration and is considered a significant advancement in hepatitis B prevention due to its improved immunogenicity and convenience for patients.
In addition to HEPLISAV-B, Dynavax also has a robust pipeline of vaccine candidates in various stages of clinical development. These include investigational vaccines for the prevention of pertussis (whooping cough), universal influenza, and COVID-19.
Dynavax collaborates with pharmaceutical and academic partners to further enhance its vaccine portfolio and leverage industry expertise. The company aims to make a positive impact on public health by addressing unmet medical needs and providing effective vaccines to prevent infectious diseases.